NCX-466
| NCX-466 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
NCX-466 is a novel pharmacological compound currently under investigation for its potential therapeutic applications in the treatment of glaucoma and other ocular diseases. It belongs to a class of drugs known as nitric oxide-donating compounds, which are designed to release nitric oxide (NO) in a controlled manner to exert beneficial effects on intraocular pressure and ocular blood flow.
Mechanism of Action[edit]
NCX-466 functions primarily by releasing nitric oxide, a potent vasodilator, which helps to lower intraocular pressure (IOP) by enhancing aqueous humor outflow through the trabecular meshwork and Schlemm's canal. The release of NO also improves ocular blood flow, which may provide neuroprotective benefits to the optic nerve, a critical factor in the management of glaucoma.
Pharmacokinetics[edit]
The pharmacokinetic profile of NCX-466 is characterized by its ability to deliver nitric oxide in a sustained manner, ensuring prolonged therapeutic effects. The compound is designed to be metabolized in ocular tissues, where it releases NO locally, minimizing systemic exposure and potential side effects.
Clinical Trials[edit]
As of the latest updates, NCX-466 is undergoing clinical trials to evaluate its safety, efficacy, and optimal dosing regimens. Preliminary results have shown promise in reducing intraocular pressure in patients with open-angle glaucoma, with a favorable safety profile.
Potential Benefits[edit]
The use of NCX-466 in glaucoma therapy offers several potential benefits:
- Improved IOP Control: By enhancing aqueous humor outflow, NCX-466 effectively reduces intraocular pressure, a key factor in glaucoma management.
- Neuroprotection: The NO-mediated improvement in ocular blood flow may protect retinal ganglion cells from ischemic damage.
- Reduced Side Effects: Localized NO release minimizes systemic side effects commonly associated with other glaucoma medications.
Challenges and Considerations[edit]
While NCX-466 shows promise, several challenges remain:
- Long-term Safety: The long-term effects of sustained NO release in ocular tissues need thorough investigation.
- Patient Compliance: As with any topical medication, ensuring patient adherence to treatment regimens is crucial.
Also see[edit]
References[edit]
<references/>
 | This ophthalmology article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
